Laurence C. Eisenlohr, VMD, PhD

Contact Dr. Eisenlohr

233 South Tenth Street
Bluemle Life Sciences Building, Room 730
Philadelphia, PA 19107

(215) 503-4540
(215) 923-4153 fax


University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, VMD - 1983
University of Pennsylvania Biomedical Graduate Studies, Philadelphia, PA, PhD, Immunology - 1988

Expertise and Research Interests

Antigen Processing and Presentation, Antiviral Immunity, T cell responses and memory, Vaccine Development Cancer immunotherapy Autoimmunity

My laboratory has four areas of interest that are relevant to vaccine development:

  • Processing and presentation for MHC class I-restricted T cell recognition. Our goals are to identify the cellular elements that participate in and modulate antigen processing and to understand how form of the antigen influences the efficiency with which it is processed. Ultimately, we are interested in how these factors impact the quantity/quality of CD8+ T cell responses.
  • Processing and presentation for MHC class II-restricted T cell recognition. We have been focusing upon epitopes within the two glycoproteins of influenza virus, hemagglutinin and neuraminidase. These biologically active and immunologically relevant proteins have been immensely useful in elucidating antigen processing pathways that are distinct from the conventional “endosomal” pathway.
  • Dynamics of CD8+ T cell responses and memory. Using tools generated for our studies of MHC class I-restricted antigen processing, we have been investigating the impact that antigen dose has upon the magnitude of the T cell response and the character of the resulting memory population.
  • Cancer immunotherapy. We have: 1) generated and characterized a GM-CSF-producing vaccinia virus that was subsequently tested in a melanoma clinical trial. 2) carried out chemical analysis of hapten-modified autologous melanoma cells, which can have a therapeutic effect when injected back into the patient. 3) generated a targeted transgenic mouse that inducibly expresses surrogate “self” antigen. With this model, we are able to investigate the evolution of tolerance to a neoantigen expressed for the first time (like a tumor-specific antigen) at different stages of life.